2024-11-28 06:25:44
Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer
Health/ 2023-07-22
Menarini Group's Elacestrant Market...

Elacestrant,if approved,would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from seco...

I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022
Corporate/ 2023-07-24
I-Mab to Report Business and Corporate U...

- Major updates will focus on global clinical development of core assets,upcoming milestones and financial results

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release